FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3083465060> ?p ?o ?g. }

• W3083465060 endingPage "1765" @default.
• W3083465060 startingPage "1757" @default.
• W3083465060 abstract "PurposeTo determine the efficacy and safety of sentinel lymph node biopsy (SLNB) in the management of eyelid and conjunctival malignancy.MethodsA literature search was performed in August 2019 and January 2020 for articles published in English in the PubMed and Cochrane Library databases. This search yielded 151 articles that were reviewed for relevancy, of which 27 were deemed to have met the inclusion criteria for this assessment. The data from these articles were abstracted and the articles were rated for strength of evidence by the panel methodologist.ResultsAll 27 studies were rated level III, and a total of 197 SLNBs were reported. Diagnoses included conjunctival and eyelid cutaneous melanoma (85 and 42 patients, respectively), sebaceous gland carcinoma (35 patients), squamous cell carcinoma (26 patients), Merkel cell carcinoma (6 patients), pigmented epithelioid melanocytoid tumor (1 patient), mucoepidermoid carcinoma (1 patient), and signet ring carcinoma (1 patient). Tracer was found in regional lymph nodes in 100% of patients in 21 of 27 articles and in 191 of 197 patients overall. The number of lymph nodes removed ranged from 1 to 16, with most ranging from 1 to 5. Tumor-positive lymph nodes were found in 33 of 197 patients (16.8%), prompting recommendations for adjuvant treatments. Survival data were reported for 16 of these patients, with follow-up periods ranging from 3 to 36 months (average, 12.7 months). Fourteen of 16 patients received adjuvant treatments. Nine were alive and well, 1 was alive with metastases, and 6 had died of metastatic disease (including 2 patients who declined additional treatment). False-negative SLNB results were reported in 5 articles involving 9 of 197 procedures (4.6%). Complications were documented in 7 of 27 articles and included transient facial nerve weakness, persistent blue dye staining of the conjunctiva, neck hematoma, and suture abscess.ConclusionsSentinel lymph node biopsy is a promising procedure in patients with eyelid and conjunctival malignancy, and it is useful in identifying sentinel lymph nodes. However, at present, insufficient evidence exists showing that SLNB improves patient outcomes and survival. Recognition of microscopic metastatic disease may prove beneficial in staging and guiding adjuvant therapy. To determine the efficacy and safety of sentinel lymph node biopsy (SLNB) in the management of eyelid and conjunctival malignancy. A literature search was performed in August 2019 and January 2020 for articles published in English in the PubMed and Cochrane Library databases. This search yielded 151 articles that were reviewed for relevancy, of which 27 were deemed to have met the inclusion criteria for this assessment. The data from these articles were abstracted and the articles were rated for strength of evidence by the panel methodologist. All 27 studies were rated level III, and a total of 197 SLNBs were reported. Diagnoses included conjunctival and eyelid cutaneous melanoma (85 and 42 patients, respectively), sebaceous gland carcinoma (35 patients), squamous cell carcinoma (26 patients), Merkel cell carcinoma (6 patients), pigmented epithelioid melanocytoid tumor (1 patient), mucoepidermoid carcinoma (1 patient), and signet ring carcinoma (1 patient). Tracer was found in regional lymph nodes in 100% of patients in 21 of 27 articles and in 191 of 197 patients overall. The number of lymph nodes removed ranged from 1 to 16, with most ranging from 1 to 5. Tumor-positive lymph nodes were found in 33 of 197 patients (16.8%), prompting recommendations for adjuvant treatments. Survival data were reported for 16 of these patients, with follow-up periods ranging from 3 to 36 months (average, 12.7 months). Fourteen of 16 patients received adjuvant treatments. Nine were alive and well, 1 was alive with metastases, and 6 had died of metastatic disease (including 2 patients who declined additional treatment). False-negative SLNB results were reported in 5 articles involving 9 of 197 procedures (4.6%). Complications were documented in 7 of 27 articles and included transient facial nerve weakness, persistent blue dye staining of the conjunctiva, neck hematoma, and suture abscess. Sentinel lymph node biopsy is a promising procedure in patients with eyelid and conjunctival malignancy, and it is useful in identifying sentinel lymph nodes. However, at present, insufficient evidence exists showing that SLNB improves patient outcomes and survival. Recognition of microscopic metastatic disease may prove beneficial in staging and guiding adjuvant therapy." @default.
• W3083465060 created "2020-09-11" @default.
• W3083465060 creator A5001078382 @default.
• W3083465060 creator A5009621636 @default.
• W3083465060 creator A5035474657 @default.
• W3083465060 creator A5042267117 @default.
• W3083465060 creator A5043137201 @default.
• W3083465060 creator A5070402328 @default.
• W3083465060 creator A5074426568 @default.
• W3083465060 date "2020-12-01" @default.
• W3083465060 modified "2023-10-12" @default.
• W3083465060 title "Sentinel Lymph Node Biopsy for Eyelid and Conjunctival Malignancy" @default.
• W3083465060 cites W1606468033 @default.
• W3083465060 cites W1979695182 @default.
• W3083465060 cites W1982766208 @default.
• W3083465060 cites W1995808677 @default.
• W3083465060 cites W2002642179 @default.
• W3083465060 cites W2008589687 @default.
• W3083465060 cites W2017373068 @default.
• W3083465060 cites W2017403445 @default.
• W3083465060 cites W2034006647 @default.
• W3083465060 cites W2034375896 @default.
• W3083465060 cites W2036914109 @default.
• W3083465060 cites W2047554765 @default.
• W3083465060 cites W2051804361 @default.
• W3083465060 cites W2058590558 @default.
• W3083465060 cites W2061147876 @default.
• W3083465060 cites W2066490546 @default.
• W3083465060 cites W2068718254 @default.
• W3083465060 cites W2093920695 @default.
• W3083465060 cites W2099176807 @default.
• W3083465060 cites W2101895635 @default.
• W3083465060 cites W2143422545 @default.
• W3083465060 cites W2145956339 @default.
• W3083465060 cites W2151776922 @default.
• W3083465060 cites W2206820851 @default.
• W3083465060 cites W2312366657 @default.
• W3083465060 cites W2532943532 @default.
• W3083465060 cites W2755718024 @default.
• W3083465060 cites W2794426311 @default.
• W3083465060 cites W4243601620 @default.
• W3083465060 doi "https://doi.org/10.1016/j.ophtha.2020.07.031" @default.
• W3083465060 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32698034" @default.
• W3083465060 hasPublicationYear "2020" @default.
• W3083465060 type Work @default.
• W3083465060 sameAs 3083465060 @default.
• W3083465060 citedByCount "17" @default.
• W3083465060 countsByYear W30834650602020 @default.
• W3083465060 countsByYear W30834650602021 @default.
• W3083465060 countsByYear W30834650602022 @default.
• W3083465060 countsByYear W30834650602023 @default.
• W3083465060 crossrefType "journal-article" @default.
• W3083465060 hasAuthorship W3083465060A5001078382 @default.
• W3083465060 hasAuthorship W3083465060A5009621636 @default.
• W3083465060 hasAuthorship W3083465060A5035474657 @default.
• W3083465060 hasAuthorship W3083465060A5042267117 @default.
• W3083465060 hasAuthorship W3083465060A5043137201 @default.
• W3083465060 hasAuthorship W3083465060A5070402328 @default.
• W3083465060 hasAuthorship W3083465060A5074426568 @default.
• W3083465060 hasBestOaLocation W30834650601 @default.
• W3083465060 hasConcept C121608353 @default.
• W3083465060 hasConcept C126322002 @default.
• W3083465060 hasConcept C126838900 @default.
• W3083465060 hasConcept C141071460 @default.
• W3083465060 hasConcept C142724271 @default.
• W3083465060 hasConcept C16005928 @default.
• W3083465060 hasConcept C2775934546 @default.
• W3083465060 hasConcept C2776835612 @default.
• W3083465060 hasConcept C2777546739 @default.
• W3083465060 hasConcept C2777658100 @default.
• W3083465060 hasConcept C2778342957 @default.
• W3083465060 hasConcept C2779399171 @default.
• W3083465060 hasConcept C2779720271 @default.
• W3083465060 hasConcept C2780212769 @default.
• W3083465060 hasConcept C2780849966 @default.
• W3083465060 hasConcept C2780859518 @default.
• W3083465060 hasConcept C2781302119 @default.
• W3083465060 hasConcept C502942594 @default.
• W3083465060 hasConcept C530470458 @default.
• W3083465060 hasConcept C71924100 @default.
• W3083465060 hasConceptScore W3083465060C121608353 @default.
• W3083465060 hasConceptScore W3083465060C126322002 @default.
• W3083465060 hasConceptScore W3083465060C126838900 @default.
• W3083465060 hasConceptScore W3083465060C141071460 @default.
• W3083465060 hasConceptScore W3083465060C142724271 @default.
• W3083465060 hasConceptScore W3083465060C16005928 @default.
• W3083465060 hasConceptScore W3083465060C2775934546 @default.
• W3083465060 hasConceptScore W3083465060C2776835612 @default.
• W3083465060 hasConceptScore W3083465060C2777546739 @default.
• W3083465060 hasConceptScore W3083465060C2777658100 @default.
• W3083465060 hasConceptScore W3083465060C2778342957 @default.
• W3083465060 hasConceptScore W3083465060C2779399171 @default.
• W3083465060 hasConceptScore W3083465060C2779720271 @default.
• W3083465060 hasConceptScore W3083465060C2780212769 @default.
• W3083465060 hasConceptScore W3083465060C2780849966 @default.
• W3083465060 hasConceptScore W3083465060C2780859518 @default.
• W3083465060 hasConceptScore W3083465060C2781302119 @default.
• W3083465060 hasConceptScore W3083465060C502942594 @default.

• next